What are the supply-side dynamics for cytosine in China's pharmaceutical intermediate market?

What are the supply-side dynamics for cytosine in China's pharmaceutical intermediate market?
China's cytosine supply is concentrated among a few specialized producers, including listed companies like Tuoxin Pharmaceutical, which lists cytosine and 5-fluorocytosine among its main products. Recent capacity adjustments reflect a shifting landscape: one project in Henan plans to cut 5-fluorocytosine output while expanding cytosine capacity by 300 tons per year, while another aims to raise 5-fluorocytosine capacity from 150 to 450 tons annually. These moves indicate that producers are rebalancing portfolios toward cytosine as a core intermediate, likely due to steady demand from antiviral APIs and potential supply tightness. The market remains fragmented, with smaller players like Xiayi Pharma also active, but environmental and regulatory pressures are pushing consolidation toward larger, compliant manufacturers, which could affect price stability in the near term.